步长制药
(603858)
| 流通市值：175.31亿 | | | 总市值：175.31亿 |
| 流通股本：11.06亿 | | | 总股本：11.06亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,640,556,945.44 | 13,245,133,303.78 | 9,983,222,406.98 | 6,957,677,365.77 |
| 营业收入 | 2,640,556,945.44 | 13,245,133,303.78 | 9,983,222,406.98 | 6,957,677,365.77 |
| 二、营业总成本 | 2,473,516,485.85 | 12,225,169,654.54 | 9,084,010,303.77 | 6,280,702,115.72 |
| 营业成本 | 1,091,518,427.21 | 4,218,281,873.36 | 3,128,714,932.05 | 2,178,725,257 |
| 税金及附加 | 40,711,266.82 | 215,360,630.01 | 161,541,173.34 | 111,863,752.96 |
| 销售费用 | 1,062,868,990.37 | 6,368,841,921.67 | 4,840,202,480.41 | 3,378,867,884.66 |
| 管理费用 | 204,645,664.71 | 995,941,119.87 | 737,726,941.86 | 474,564,863.18 |
| 研发费用 | 46,021,307.86 | 335,081,014.06 | 151,009,893.22 | 100,303,179.79 |
| 财务费用 | 27,750,828.88 | 91,663,095.57 | 64,814,882.89 | 36,377,178.13 |
| 其中:利息费用 | 29,353,007.06 | 109,931,398.82 | 84,865,781.74 | 52,547,391.12 |
| 其中:利息收入 | 1,842,320.62 | 18,823,380.16 | 22,106,303.56 | 17,447,961.06 |
| 加:公允价值变动收益 | -1,957,899.34 | -2,356,116.14 | -1,178,058.07 | 1,178,058.08 |
| 加:投资收益 | -2,122,197.44 | 21,292,517.55 | 17,848,564.47 | 19,373,338.4 |
| 资产处置收益 | 1,236.95 | 1,529,515.21 | 636,506.99 | 16,168.81 |
| 资产减值损失(新) | -127,871.52 | -700,721,937.96 | -1,741,392.04 | -9,457,187.04 |
| 信用减值损失(新) | 25,954,623.03 | -17,320,669.38 | 13,464,203.34 | 7,484,315.06 |
| 其他收益 | 24,340,405.14 | 113,631,877.22 | 192,354,339.2 | 181,822,601.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 213,128,756.41 | 436,018,835.74 | 1,120,596,267.1 | 877,392,545.26 |
| 加:营业外收入 | 334,017.86 | 7,838,466.41 | 2,568,598.5 | 1,265,001.97 |
| 减:营业外支出 | 3,059,632.3 | 49,300,519.68 | 42,362,240.92 | 14,371,320.51 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 210,403,141.97 | 394,556,782.47 | 1,080,802,624.68 | 864,286,226.72 |
| 减:所得税费用 | 122,704,270.11 | 242,691,584.16 | 249,569,040.6 | 180,705,210.58 |
| 六、净利润 | 87,698,871.86 | 151,865,198.31 | 831,233,584.08 | 683,581,016.15 |
| 持续经营净利润 | 87,698,871.86 | 151,865,198.31 | 831,233,584.08 | 683,581,016.15 |
| 归属于母公司股东的净利润 | 114,015,551.69 | 318,973,324.8 | 925,143,634.85 | 746,138,249.89 |
| 少数股东损益 | -26,316,679.83 | -167,108,126.49 | -93,910,050.77 | -62,557,233.75 |
| (一)基本每股收益 | 0.1 | 0.29 | 0.84 | 0.67 |
| (二)稀释每股收益 | 0.1 | 0.29 | 0.84 | 0.67 |
| 八、其他综合收益 | -203,622.75 | -298,746.38 | -535,905.73 | -593,320.8 |
| 归属于母公司股东的其他综合收益 | -203,622.75 | -298,746.38 | -535,905.73 | -593,320.8 |
| 九、综合收益总额 | 87,495,249.11 | 151,566,451.93 | 830,697,678.35 | 682,987,695.35 |
| 归属于母公司股东的综合收益总额 | 113,811,928.94 | 318,674,578.42 | 924,607,729.12 | 745,544,929.09 |
| 归属于少数股东的综合收益总额 | -26,316,679.83 | -167,108,126.49 | -93,910,050.77 | -62,557,233.75 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-28 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |